Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Acura Pharmaceuticals Inc. (NASDAQ:ACUR) lost $0.17 (14%) to $1.06 last week after saying FDA advised the company that data from the Phase II Study 301 are "insufficient to support an intranasal abuse deterrence claim" for Acura's Vycavert, an oral, immediate-release formulation of hydrocodone with acetaminophen that uses the company's Aversion abuse-deterrent technology.

Acura previously said it expected to submit an NDA to FDA for the product this half. The company said it will determine a revised timeline following a meeting with FDA. At least one analyst downgraded the stock (see "Analyst Picks" A15).

The contingent value right for Genzyme Corp. was up $0.05 to $0.52 on Friday after Genzyme said FDA accepted for review a resubmitted sBLA for Lemtrada alemtuzumab to

Read the full 1209 word article

How to gain access

Continue reading with a
two-week free trial.